Literature DB >> 16699864

Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B.

Ken Sato, Hitoshi Takagi, Satoru Kakizaki, Naondo Sohara, Masatomo Mori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16699864     DOI： 10.1007/s00535-006-1770-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  8 in total

1.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

Authors:  Scott K Fung; Pietro Andreone; Steve H Han; K Rajender Reddy; Arie Regev; Emmet B Keeffe; Munira Hussain; Carmela Cursaro; Pamela Richtmyer; Jorge A Marrero; Anna S F Lok
Journal:  J Hepatol       Date:  2005-07-07       Impact factor: 25.083

2.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

3.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

Authors:  Marie-Noëlle Brunelle; Anne-Carole Jacquard; Christian Pichoud; David Durantel; Sandra Carrouée-Durantel; Jean-Pierre Villeneuve; Christian Trépo; Fabien Zoulim
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

4.  Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Authors:  R Perrillo; E Schiff; E Yoshida; A Statler; K Hirsch; T Wright; K Gutfreund; P Lamy; A Murray
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

5.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

6.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

7.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Authors:  Peter Angus; Rhys Vaughan; Shelly Xiong; Huiling Yang; William Delaney; Craig Gibbs; Carol Brosgart; Danielle Colledge; Rosalind Edwards; Anna Ayres; Angeline Bartholomeusz; Stephen Locarnini
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

8.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; K Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; R Ebrahimi; S Xiong; Carol L Brosgart
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.